您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Finerenone
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Finerenone
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Finerenone图片
规格:98%
分子量:378.42
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议

产品介绍
Finerenone(BAY94-8862)是第三代选择性、具有口服活性的、非甾体类盐皮质激素受体(MR)拮抗剂(IC50=18nM)。与糖皮质激素受体(GR)、雄激素受体(AR)和孕酮受体(AR)相比,Finerenone表现出良好的选择性(>500-fold)。Finerenone在心肾疾病研究中具有潜在的应用前景,如2型糖尿病和慢性肾脏疾病。
货号:ajcx30654
CAS:1050477-31-0
分子式:C21H22N4O3
分子量:378.42
溶解度:N/A
纯度:98%
存储:Store at -20°C
库存:现货

Background:

Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC50=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease[1][2].


Finerenone (BAY 94-8862) lowers albuminuria by >40% and significantly reduces systolic blood pressure (SBP) in Munich Wistar FrÖmter (MWF) rat[1]. Animal Model: Twelve-week-old MWF rat[1]

[1]. BÄrfacker L, et al. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem. 2012;7(8):1385-1403. [2]. GonzÁlez-BlÁzquez R, et al. Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress. Front Pharmacol. 2018;9:1131. Published 2018 Oct 9.